anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A drug delivery system, such as an inhalator 1, is disclosed. It comprises a body, mouthpiece 7 and a microphone 9. The processing circuitry 13 is operable to process the signal obtained from the microphone 9 to determine the operating conditions of the drug delivery device. Specifically, the processing circuitry 13 comprises means for: tracking energy in an acoustic signal received from a microphone 9 during inhalation; converting said energy into a flow profile 41 using stored first calibration data; processing said signal to detect the timing of the delivery of the medicament during inhalation; comparing the detected timing relative to said flow profile with stored second calibration data to determine if the delivery meets a desired delivery protocol 37. Preferably, the frequency of the inhalation cycle and the frequency of the drug dispensation are measured and compared with ideal parameters. The device is preferably used for training purposes. Also disclosed is a drug delivery system comprising processing circuitry with means for determining a dominant frequency or a harmonic thereof in an acoustic signal received from a microphone. The determined dominant or harmonic frequency is then converted into a flow rate value using stored calibration data.
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.  The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
Pocket motifs and their amino acid positions of HLA molecules are known to govern antigen presentation to effector cells. Our objective was to analyse their influence on the risk of graft-versus-host disease (GVHD) and relapse after umbilical cord blood transplant (UCBT). The transplant characteristics of 849 patients with acute leukaemia were obtained from the Eurocord/EBMT database. Higher acute (a) GVHD was associated with homozygosity of UCB HLA-C amino acid positions 77 and 80 (NN/KK) (p = 0.008). Severe aGVHD was associated with HLA-A pocket B YSAVMENVHY motif (p = 0.002) and NN and RR genotypes of the HLA-C amino acid positions 77 and 156 (p = 0.006 and p = 0.002). Such risk was also increased in case of recipient and UCB mismatches in P4 (p < 0.0001) and P9 (p = 0.003) pockets of HLA-DQB1 alleles. For chronic GVHD, the pocket B YYAVMEISNY motif of the HLA-B*15:01 allele and the absence of mismatch between recipient and UCB in the P6 pocket of HLA-DRB1 were associated with a lower risk (p = 0.0007 and p = 0.0004). In relapse, both UCB pocket B YFAVMENVHY belonging to HLA-A*32:01 and recipient pocket B YDSVGENYQY motif of the HLA-C*07:01 allele were associated with higher risk (p = 0.0026 and p = 0.015). We provide clues on HLA-mediated cellular interactions and their role in the development of GVHD and relapse.
BACKGROUND: ChatGPT-4 is a large language model with promising healthcare applications. However, its ability to analyze complex clinical data and provide consistent results is poorly known. Compared to validated tools, this study evaluated ChatGPT-4's risk stratification of simulated patients with acute nontraumatic chest pain.
METHODS: Three datasets of simulated case studies were created: one based on the TIMI score variables, another on HEART score variables, and a third comprising 44 randomized variables related to non-traumatic chest pain presentations. ChatGPT-4 independently scored each dataset five times. Its risk scores were compared to calculated TIMI and HEART scores. A model trained on 44 clinical variables was evaluated for consistency.
RESULTS: ChatGPT-4 showed a high correlation with TIMI and HEART scores (r = 0.898 and 0.928, respectively), but the distribution of individual risk assessments was broad. ChatGPT-4 gave a different risk 45-48% of the time for a fixed TIMI or HEART score. On the 44-variable model, a majority of the five ChatGPT-4 models agreed on a diagnosis category only 56% of the time, and risk scores were poorly correlated (r = 0.605).
CONCLUSION: While ChatGPT-4 correlates closely with established risk stratification tools regarding mean scores, its inconsistency when presented with identical patient data on separate occasions raises concerns about its reliability. The findings suggest that while large language models like ChatGPT-4 hold promise for healthcare applications, further refinement and customization are necessary, particularly in the clinical risk assessment of atraumatic chest pain patients.
The claimed group of inventions relates to the field of pharmacology and medicine. The pharmacological composition is intended for intra-nasal administration and enables an active substance to be supplied directly to the brain, by-passing the blood-brain barrier. The composition comprises a base container, a pharmacologically active component and a surface-modifying substance. Porous particles of an inorganic substance are used as the container, and the surface of the container is modified with surfactants, polymers or with a combination thereof. The containers made of an inorganic substance have a size in the range from 300 to 5000 nm. Inorganic substances selected from a group consisting of metal salts or oxides, for example calcium carbonate or titanium oxide, in the form of porous particles of a micron or sub-micron size, are used as the base container. For the surface-modifying substance, use is made of surfactants selected from polysorbates, or of polymers, selected from a group consisting of glycosaminoglycans, polypeptides, or combinations thereof. The method for producing the designated composition comprises producing the base container, sorbing the pharmacologically active substance in volumes of the pores in said container, and modifying the surface of said container. The base container is synthesized from inorganic substances in the form of porous particles of a micron or sub-micron size, and the surface of the designated particles of the base container is additionally modified with polymers selected from the group consisting of glycosaminoglycans or polypeptides, or with surfactants selected from the group consisting of polysorbates, or with combinations thereof.
Gastric cancer is one of the most common malignancies in China with incidence and mortality both ranking the 2nd among malignancies in China. Surgery is the only possible way to cure gastric cancer, however, over 80-90% of gastric cancer patients in China are in advanced stage. Locally advanced gastric cancer (cT3-4aN+M0) could be cured by multi-disciplinary therapies including surgery, chemotherapy and radiotherapy. Neoadjuvant chemotherapy can downstage T and N stage, increase the resectability of tumor, and finally improve the long-term survival. However, the therapeutic effects remain unsatisfactory. PD-1 antibody has demonstrated its efficacy in metastatic gastric cancer and has been proved to be effective in neoadjuvant setting in lung cancer and melanoma. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced gastric cancer could be a novel therapy to increase response rate and resectability and reduce recurrence rate. JS001 in this study is a Chinese anti-PD-1 monoclonal antibody for injection which has been approved for melanoma. This study is a multi-center, open-label, randomized phase II clinical trial to evaluate tolerability, safety and efficacy of JS001 in combination with perioperative chemotherapy in locally advanced gastric cancer.
The invention provides new application of Gypensapogenin B in medicine, namely application of Gypensapogenin B in preparing a medicine for treating acute gout. Experiment research results indicate that t Gypensapogenin B has the protective effect on acute gout models with human blood vessel endothelium cells damage cuased by urate, and restrains ICAM (intercellular adhesion molecule)-1 expression, so that Gypensapogenin B can be used for preparing the medicine for treating acute gout. The application of Gypensapogenin B in preparing the medicine for treating acute gout, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the prevention activity of Gypensapogenin B to acute gout is extremely strong, so that no possibility for providing any prompt by other compounds exists. Gypensapogenin B has outstanding actual characteristics. Meanwhile, Gypensapogenin B has outstanding progress when being used for preventing and curing acute gout.
PURPOSE:To obtain a large amount of cultured vegetable cells having blood- coagulation activity and psychotropic antispasmodic activity, stably, by culturing the tissue or cell of a vegetable belonging to Hydrocotyle genus or Centella genus in a medium. CONSTITUTION:The objective cultured vegetable cell can be produced by culturing the tissue (e.g. terminal bud or lateral bud) or cell of a vegetable belonging to Hydrocotyle genus or Centella genus (e.g. Hydrocotyle sibthorpioides, Hydrocotyle japonica, etc.) in a medium. The medium is preferably the one produced by using an inorganic synthetic agar medium as a base medium and adding a carbon source, yeast extract, vitamins, amino acids, etc., and further an auxin-active substance (e.g. 2,4-dichlorophenoxyacetic acid) and/or a cytokinin-active substance (e.g. benzyladenine). A blood coagulant and a psychotropic antispasmodic agent can be produced by extracting the obtained culture cell with a solvent, etc.
A cohort of 5,000 diabetic patients with different stages of DR will be recruited and followed for an average of 2 years. Each year, general data as well as ophthalmological data will be collected. Retinal images and videos of both eyes will be acquired using different imaging modalities including ultrawidefield photography, OCT and OCT angiography. The EviRed cohort will be split in two groups: one group of 1,000 patients (validation cohort) will be randomly selected during the inclusion period by unbalanced draw to be representative of the general diabetic population. Their data will be used for the validation of the algorithms. The data of the remaining 4,000 patients (training cohort) will be used to train the algorithms. The main objective will be the validation of the prognostic tool and evaluate how accurately the algorithm can predict progression to severe retinopathy in the following year. Secondary objectives will be to evaluate how accurately the algorithm can assess DR severity and individual components of severe DR, predict progression to severe retinopathy, visual decrease, occurrence of fluid in the macula area in an eye, DR progression in an eye and for a patient, as well as to compare prediction by algorithm with the one made by ophthalmologists based on the current DR classification and their clinical experience. Secondary outcome measures will be sensitivity, specificity and AUC of the algorithm for detecting DR severity and individual components of severe DR, prediction of DR progression towards a severe form of DR, visual decrease, occurrence of fluid in the macular area in an eye, as well as to predict DR progression in an eye and for a patient.

Economic study Healthcare reimbursement data will also be collected and analyzed from Health Insurance. The inclusion and follow-up period of the cohort runs from 12/21/2020 to 12/21/2024, with follow-up durations varying from 1 to 3 years.
For Oral Use Only.

The use of sodium phenylbutyrate tablets is indicated for children weighing more than 20 kg and for adults.

The usual total daily dose of sodium phenylbutyrate powder for patients with urea cycle disorders is 450 to 600 mg/kg/day in patients weighing less than 20 kg, or 9.9 to 13 g/m2/day in larger patients. The powder is to be taken in equally divided amounts with each meal or feeding (i.e., three to six times per day).

Sodium phenylbutyrate powder is indicated for oral use (via mouth, gastrostomy, or nasogastric tube) only. The powder is to be mixed with food (solid or liquid) for immediate use; however, when dissolved in water, sodium phenylbutyrate powder has been shown to be stable for up to one week at room temperature or refrigerated. Sodium phenylbutyrate, USP is very soluble in water (5 grams per 10 mL). When sodium phenylbutyrate powder is added to a liquid, only sodium phenylbutyrate, USP will dissolve, the excipients will not. The effect of food on sodium phenylbutyrate, USP has not been determined. 

Each level yellow teaspoon (enclosed) dispenses 3.2 grams of powder and 3 grams of sodium phenylbutyrate, USP. Each level blue tablespoon (enclosed) dispenses 9.1 grams of powder and 8.6 grams of sodium phenylbutyrate, USP.

Shake lightly before use.

The safety or efficacy of doses in excess of 20 grams per day has not been established.
PCT No. PCT/NL92/00054 Sec. 371 Date Sep. 20, 1993 Sec. 102(e) Date Sep. 20, 1993 PCT Filed Mar. 19, 1992 PCT Pub. No. WO92/16630 PCT Pub. Date Jan. 10, 1992The invention provides DNA sequences which code for polypeptides which are characteristic for the virulence of the pathogenic bacterium Streptococcus suis and parts thereof, and polypeptides and antibodies derived therefrom. The sequences code for a polypeptide of 90,000-120,000 daltons or a polypeptide of higher molecular weight containing such a polypeptide, and for a polypeptide of 135,000-136,000 daltons (muramidase released protein), or parts thereof. The sequences themselves, and also the polypeptides and antibodies derived therefrom, are used for diagnosis of and protection against infection by S. suis in mammals, including man.
PURPOSE:To obtain the titled pharmaceutical having improved sustained release property and local retention property, by fixing an anticancer substance and an anticoagulant on separate structures, and combining the structures together. CONSTITUTION:An anticancer substance is fixed on a structure having a form, e.g. fiber assembly, sponge, powder, monofilament, film or microcapsule, etc. and an anticoagulant, e.g. blood coagulation factor VIII, is fixed on a separate structure. The above-mentioned structures having the fixed anticancer substance and anticoagulant thereon are combined to give the aimed sustained release type pharmaceutical. The fixing of both the anticancer substance and the anticoagulant provides the sustained release type pharmaceutical capable of acting on cancers or tumors effectively for a long term, but the fixing of coexisting both will sometimes cause aggregation. The separate fixing and mixing by laminating, etc. provides the highly active pharmaceutical easily without causing aggregation.
The patients will be divided into two groups and general anesthesia will be applied to all of them. There will be no regional anesthetic technique to be performed, on the other hand, external oblique intercostal nerve block will be applied to patients in the other group before the patients are extubated. Study randomization is done with computer-generated randomization codes (computer-generated) by a physician who will not participate in patient follow-up. Interfascial plane block (external oblique intercostal block) will be given to the anesthesiologist in a sealed envelope by an independent assistant staff outside the study, the patient will not know which block is applied. The anesthetist who made the block will not participate in the pain follow-up of the patients. Postoperative pain assessment and data collection will be performed by another anesthetist blinded to the study.

For the standardization, the block procedure will be performed by an experienced anesthesiologist who has performed at least 20 previous successful and uncomplicated procedures.
Extracts prepared from red and high-pigment beetroots ( Beta vulgaris  L.) with a solvent, such as a water-containing solvent, possess antioxidant activity as demonstrated by a panel of assays. These extracts also have an ability to induce quinone reductase in Murine hepatoma cell (Hepa 1c1c7) cultured in vitro. Fractions purified from the active extracts also possess antioxidant activity and retain quinone reductase-inducing activity in the Hepa 1c1c7 cell line. The active extracts, purified by column, thin layer, and high-performance liquid chromatographic techniques, include betalains. A method of extracting a betalain includes steps of freeze-drying a source containing the betalain; grinding the freeze-dried source; and extracting the betalain from the ground source with the solvent. Additionally, the betalain extract can be isolated betalain components, such as by chromatography.
BACKGROUND: The World Health Organization (WHO) has outlined a set of targets to achieve eliminating hepatitis C by 2030. In May 2022, Lithuanian health authorities initiated a hepatitis C virus (HCV) screening program to start working towards elimination. In the program, bonus was given to general practitioners (GPs) to promote and conduct anti-HCV tests for two situations: (1) one time testing for individuals born in 1945-1994 and (2) annual HCV testing for persons who inject drugs or are living with human immunodeficiency virus (HIV) regardless of age. This study aimed to model the current viral hepatitis C epidemiological status in Lithuania and to outline the requirements for WHO elimination targets using the first-year HCV screening results.
METHODS: Individuals were invited to participate in the anti-HCV screening by GPs during routine visits. Patients who tested positive were then referred to a gastroenterologist or infectious disease doctor for further confirmatory testing. If a patient received a positive RNA test and a fibrosis staging result of ≥ F2, the doctor prescribed direct-acting antivirals. Information on the patients screened, diagnosed, and treated was obtained from the National Health Insurance Fund. The Markov disease progression model, developed by the CDA Foundation, was used to evaluate the screening program results and HCV elimination progress in Lithuania.
RESULTS: Between May 2022 and April 2023, 790,070 individuals underwent anti-HCV testing, with 11,943 individuals (1.5%) receiving positive results. Anti-HCV seroprevalence was found to be higher among males than females, 1.9% and 1.2%, respectively. Within the risk population tested, 2087 (31.1%) seropositive individuals were identified. When comparing the screening program results to WHO elimination targets through modelling, 2180 patients still need to be treated annually until 2030, along with expanding fibrosis restrictions. If an elimination approach was implemented, 1000 new infections would be prevented, while saving 150 lives and averting 90 decompensated cirrhosis cases and 110 hepatocellular carcinoma cases.
CONCLUSIONS: During the first year of the Lithuanian screening program, GPs were able to screen 44% of the target population. However, the country will not meet elimination targets as it currently stands without increasing treatment levels and lifting fibrosis restrictions.
PURPOSE:To obtain a solution having cardiotonic, analgesic an antipyretic activities, etc., and reduced bitter taste and harsh taste, by adding an extract of SENSO (dried parotid milk of Bufo bufo gargarizans) together with cyclodextrin to a solution. CONSTITUTION:SENSO extract is compounded together with cyclodextrin (e.g. beta-cyclodextrin, gamma-cyclodextrin, etc.) to a solution. SENSO is prepared by drying the milk secreted from the parotid gland of Bufo bufo gargarizans or Bufo melanosticus of Bufomidae family and is used traditionally as an important analgesic and antipyretic drug. However, SENSO has strong bitter and harsh taste to inhibit the administration in the form of liquid. The bitter and harsh taste of SENSO can be eliminated even in a liquid containing the active component of SENSO in high titer by adding beta-cyclodextrin and/or gamma-cyclodextrin to the SENSO extract. The amount of cyclodextrin is 5-300 pts., preferably 50-150 pts. per 1 pt. of SENSO.
It is known that over half of previously surveyed surgeons performing Robot-Assisted Laparoscopic Surgery (RALS) and three-quarters of those performing Traditional Laparoscopic Surgery (TLS) experience intraoperative pain. This survey study aimed to expand upon the ongoing impact of that pain as well as perceived tool usability associated with TLS and RALS, for which considerably less documentation exists. A survey regarding the presence and impact, either immediate or ongoing, of intraoperative pain and Likert scale questions regarding tool usability was administered to TLS and RALS surgeons on the European Association for Endoscopic Surgery (EAES) mailing list. Prevalence statistics as well as trends based on biological sex and glove size were obtained from the 323 responses. Most respondents were right-handed European males (83-88%) with a medium glove size (55.8%). Moderate or severe shoulder symptoms were experienced by one-third of TLS surgeons. Twenty-one percent of RALS surgeons experienced neck symptoms that impacted their concentration. Small-handed surgeons experienced wrist symptoms significantly more frequently than large-handed surgeons, regardless of modality. RALS was associated with a significantly more optimal back and wrist posture compared to TLS. TLS surgeons reported increased ease with applying and moderating force while operating. These results suggest that intraoperative pain may be severe enough in many cases to interfere with surgeon concentration, negatively impacting patient care. Continuing to understand the relationship between tool usability and comfort is crucial in guaranteeing the health and well-being of both surgeons and patients.